<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Ikonisys Sa — News on 6ix</title>
<link>https://6ix.com/company/ikonisys-sa-1</link>
<description>Latest news and press releases for Ikonisys Sa on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 11 May 2026 16:08:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/ikonisys-sa-1" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d52a90beedb30cb6f6aeeb.webp</url>
<title>Ikonisys Sa</title>
<link>https://6ix.com/company/ikonisys-sa-1</link>
</image>
<item>
<title>Aliko Scientific Signs Strategic Memorandum of Understanding with Cellay Inc. and Secures First Commercial Customer in Arizona</title>
<link>https://6ix.com/company/ikonisys-sa-1/news/aliko-scientific-signs-strategic-memorandum-of-understanding-with-cellay-inc-and-secures-first-commercial-customer-in-arizona</link>
<guid isPermaLink="true">https://6ix.com/company/ikonisys-sa-1/news/aliko-scientific-signs-strategic-memorandum-of-understanding-with-cellay-inc-and-secures-first-commercial-customer-in-arizona</guid>
<pubDate>Mon, 11 May 2026 16:08:00 GMT</pubDate>
<description>PARIS, May 11, 2026--Regulatory News: Aliko Scientific SA ("Aliko Scientific" or the "Company") (Euronext Growth Paris: ALIKO), an industrial and financial holding company focused on advanced oncology diagnostics, announces the signing of a strategic Memorandum of Understanding ("MoU") with Cellay Inc., a U.S.-based company headquartered in Cambridge, Massachusetts and specialized in the development of Same Day OligoFISH® probes for chromosome enumeration applications.</description>
</item>
<item>
<title>Ikonisys: Hospitex International Signs Strategic Distribution Agreement With Naturneed for Urine24, Strengthening Its Commercial Footprint in the Italian Urology Diagnostics Market</title>
<link>https://6ix.com/company/ikonisys-sa-1/news/ikonisys-hospitex-international-signs-strategic-distribution-agreement-with-naturneed-for-urine24-strengthening-its-commercial-footprint-in-the-italian-urology-diagnostics-market</link>
<guid isPermaLink="true">https://6ix.com/company/ikonisys-sa-1/news/ikonisys-hospitex-international-signs-strategic-distribution-agreement-with-naturneed-for-urine24-strengthening-its-commercial-footprint-in-the-italian-urology-diagnostics-market</guid>
<pubDate>Tue, 10 Mar 2026 17:00:00 GMT</pubDate>
<description>PARIS, March 10, 2026--Regulatory News: Hospitex International, part of Aliko Scientific Group (Ticker: ALIKO), announces the signing of a strategic distribution agreement with Naturneed for the commercialization in Italy of Urine24, the innovative non-invasive test for the early screening of bladder cancer.</description>
</item>
<item>
<title>Aliko Scientific: Outstanding Success at WHX Labs Dubai With 172 Commercial Leads and Strong Global Interest in the New Integrated Oncology Diagnostics Platform</title>
<link>https://6ix.com/company/ikonisys-sa-1/news/aliko-scientific-outstanding-success-at-whx-labs-dubai-with-172-commercial-leads-and-strong-global-interest-in-the-new-integrated-oncology-diagnostics-platform</link>
<guid isPermaLink="true">https://6ix.com/company/ikonisys-sa-1/news/aliko-scientific-outstanding-success-at-whx-labs-dubai-with-172-commercial-leads-and-strong-global-interest-in-the-new-integrated-oncology-diagnostics-platform</guid>
<pubDate>Tue, 24 Feb 2026 17:00:00 GMT</pubDate>
<description>PARIS, February 24, 2026--Regulatory News: Aliko Scientific SA (Ticker: ALIKO) previously Ikonisys SA, announces a highly successful first market appearance at WHX Labs Dubai, the world’s largest medical trade exhibition and a key global reference event for the diagnostics industry.</description>
</item>
<item>
<title>Aliko Scientific: Francesco Trisolini Appointed as New Group CEO to Pursue the Implementation of the Approved Industrial Plan</title>
<link>https://6ix.com/company/ikonisys-sa-1/news/aliko-scientific-francesco-trisolini-appointed-as-new-group-ceo-to-pursue-the-implementation-of-the-approved-industrial-plan-1</link>
<guid isPermaLink="true">https://6ix.com/company/ikonisys-sa-1/news/aliko-scientific-francesco-trisolini-appointed-as-new-group-ceo-to-pursue-the-implementation-of-the-approved-industrial-plan-1</guid>
<pubDate>Wed, 18 Feb 2026 17:00:00 GMT</pubDate>
<description>PARIS, February 18, 2026--Regulatory News: Aliko Scientific SA (Ikonisys SA – Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique, fully automated solution for medical analysis laboratories, following the recent capital increase, announces that the Board of Directors has ratified the decision taken by the Shareholders’ General Assembly to appoint Francesco Trisolini as Chief Executive Officer of the Group.</description>
</item>
<item>
<title>Ikonisys finalized a Capital Increase and Debt Conversion of EUR 2.72 million with strategic investment from Avantgarde Srl and Alberto Previtali</title>
<link>https://6ix.com/company/ikonisys-sa-1/news/ikonisys-finalized-a-capital-increase-and-debt-conversion-of-eur-272-million-with-strategic-investment-from-avantgarde-srl-and-alberto-previtali-1</link>
<guid isPermaLink="true">https://6ix.com/company/ikonisys-sa-1/news/ikonisys-finalized-a-capital-increase-and-debt-conversion-of-eur-272-million-with-strategic-investment-from-avantgarde-srl-and-alberto-previtali-1</guid>
<pubDate>Fri, 19 Dec 2025 17:09:00 GMT</pubDate>
<description>PARIS, December 19, 2025--Regulatory News: Ikonisys SA (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique, fully automated solution for medical analysis laboratories (the "Issuer"), today announces a capital increase in cash for a total of €1.5 million by way of a private placement, and the request to convert €1.22 million of existing debt into capital. The total amount of the round is therefore of €2.72 million.</description>
</item>
<item>
<title>Ikonisys: Cytofast Auto: The First Fully Automatic Universal Monolayer Cytology Processor Is Born</title>
<link>https://6ix.com/company/ikonisys-sa-1/news/ikonisys-cytofast-auto-the-first-fully-automatic-universal-monolayer-cytology-processor-is-born-1</link>
<guid isPermaLink="true">https://6ix.com/company/ikonisys-sa-1/news/ikonisys-cytofast-auto-the-first-fully-automatic-universal-monolayer-cytology-processor-is-born-1</guid>
<pubDate>Thu, 04 Dec 2025 16:45:00 GMT</pubDate>
<description>PARIS, December 04, 2025--Regulatory News: Hospitex international, the fully owned Italian subsidiary of Aliko Scientific (Ikonisys SA, Euronext Growth Paris: ALIKO) and leader in the production of cytology medical devices, announces the start of the design of Cytofast Auto, the first fully automated and—most importantly—universal LBC (Liquid Based Cytology) processor, a project that opens a new phase not only for Hospitex, but for the entire global cytology sector.</description>
</item>
<item>
<title>Ikonisys: Hospitex Initiates International Dialogues for Pilot Projects in Oncology Diagnostics Following ADB Delegation Visit</title>
<link>https://6ix.com/company/ikonisys-sa-1/news/ikonisys-hospitex-initiates-international-dialogues-for-pilot-projects-in-oncology-diagnostics-following-adb-delegation-visit-1</link>
<guid isPermaLink="true">https://6ix.com/company/ikonisys-sa-1/news/ikonisys-hospitex-initiates-international-dialogues-for-pilot-projects-in-oncology-diagnostics-following-adb-delegation-visit-1</guid>
<pubDate>Mon, 24 Nov 2025 17:36:00 GMT</pubDate>
<description>PARIS, November 24, 2025--Regulatory News: Hospitex, the fully owned Italian subsidiary of Aliko Scientific (Ikonisys SA, Euronext Growth Paris: ALIKO) and leader in the production of cytology medical devices, announces that it is preparing the pilot project of Urine24 in the Far East, following ADB (Asian Bank Development) Delegation Visit.</description>
</item>
<item>
<title>Ikonisys SA: Hospitex Wins Public Tender at Policlinico di Bari for Cytofast Cytology Systems</title>
<link>https://6ix.com/company/ikonisys-sa-1/news/ikonisys-sa-hospitex-wins-public-tender-at-policlinico-di-bari-for-cytofast-cytology-systems-1</link>
<guid isPermaLink="true">https://6ix.com/company/ikonisys-sa-1/news/ikonisys-sa-hospitex-wins-public-tender-at-policlinico-di-bari-for-cytofast-cytology-systems-1</guid>
<pubDate>Tue, 07 Oct 2025 15:45:00 GMT</pubDate>
<description>PARIS, October 07, 2025--Regulatory News: Hospitex, the fully owned Italian subsidiary of Aliko Scientific (Ikonisys SA, Euronext Growth Paris: ALIKO) and leader in the production of cytology medical devices, has been awarded a prestigious public tender worth €353k by Policlinico di Bari, one of Southern Italy’s most prominent university hospitals and research hubs.</description>
</item>
<item>
<title>Ikonisys SA: Suspension of Trading of Shares on Euronext Growth Paris Until the Publication of the 2024 Annual Report</title>
<link>https://6ix.com/company/ikonisys-sa-1/news/ikonisys-sa-suspension-of-trading-of-shares-on-euronext-growth-paris-until-the-publication-of-the-2024-annual-report-1</link>
<guid isPermaLink="true">https://6ix.com/company/ikonisys-sa-1/news/ikonisys-sa-suspension-of-trading-of-shares-on-euronext-growth-paris-until-the-publication-of-the-2024-annual-report-1</guid>
<pubDate>Tue, 01 Jul 2025 16:11:00 GMT</pubDate>
<description>PARIS, July 01, 2025--Regulatory News: Ikonisys SA (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique, fully automated solution for medical analysis laboratories, today announces the suspension of the trading of its shares on Euronext Growth Paris. It will resume as soon as the company publishes its 2024 annual report.</description>
</item>
<item>
<title>ALIKO SCIENTIFIC (Ikonisys SA), Through Its Fully Owned Italian Subsidiary Hospitex International, Signs Exclusive Distribution Agreement for Italy with Menarini Diagnostics</title>
<link>https://6ix.com/company/ikonisys-sa-1/news/aliko-scientific-ikonisys-sa-through-its-fully-owned-italian-subsidiary-hospitex-international-signs-exclusive-distribution-agreement-for-italy-with-menarini-diagnostics-1</link>
<guid isPermaLink="true">https://6ix.com/company/ikonisys-sa-1/news/aliko-scientific-ikonisys-sa-through-its-fully-owned-italian-subsidiary-hospitex-international-signs-exclusive-distribution-agreement-for-italy-with-menarini-diagnostics-1</guid>
<pubDate>Wed, 04 Jun 2025 05:30:00 GMT</pubDate>
<description>FLORENCE, Italy & PARIS, June 04, 2025--Regulatory News: ALIKO SCIENTIFIC (Ikonisys SA) Euronext Growth: ALIKO, through its fully owned Italian subsidiary Hospitex International is pleased to announce the signing of an exclusive distribution agreement with Menarini Diagnostics, the European largest distributor in the field of pathology and IVD (in vitro diagnostics).</description>
</item>
<item>
<title>Ikonisys Announces a Further Postponement of the Publication of Its 2024 Annual Financial Report</title>
<link>https://6ix.com/company/ikonisys-sa-1/news/ikonisys-announces-a-further-postponement-of-the-publication-of-its-2024-annual-financial-report-1</link>
<guid isPermaLink="true">https://6ix.com/company/ikonisys-sa-1/news/ikonisys-announces-a-further-postponement-of-the-publication-of-its-2024-annual-financial-report-1</guid>
<pubDate>Fri, 30 May 2025 15:45:00 GMT</pubDate>
<description>PARIS, May 30, 2025--Regulatory News: Ikonisys SA (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique, fully automated solution for medical analysis laboratories, today announces another postponement of the publication of its 2024 annual financial report that will now take place on June 30, 2025, instead of the previously announced date of May 31, 2025.</description>
</item>
<item>
<title>Ikonisys Finalized a Capital Increase Through the Offsetting of Debt</title>
<link>https://6ix.com/company/ikonisys-sa-1/news/ikonisys-finalized-a-capital-increase-through-the-offsetting-of-debt-1</link>
<guid isPermaLink="true">https://6ix.com/company/ikonisys-sa-1/news/ikonisys-finalized-a-capital-increase-through-the-offsetting-of-debt-1</guid>
<pubDate>Fri, 02 May 2025 15:45:00 GMT</pubDate>
<description>PARIS, May 02, 2025--Regulatory News: Ikonisys SA (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique, fully automated solution for medical analysis laboratories (the "Issuer"), today announces a capital increase of €350k through the offsetting of part of the debt owed to two shareholders, including Cambria Equity Partners LP, and the issue of 233,334 new shares of the Company.</description>
</item>
<item>
<title>Ikonisys Announces the Postponement of the Publication of Its 2024 Annual Financial Report</title>
<link>https://6ix.com/company/ikonisys-sa-1/news/ikonisys-announces-the-postponement-of-the-publication-of-its-2024-annual-financial-report-1</link>
<guid isPermaLink="true">https://6ix.com/company/ikonisys-sa-1/news/ikonisys-announces-the-postponement-of-the-publication-of-its-2024-annual-financial-report-1</guid>
<pubDate>Fri, 25 Apr 2025 15:45:00 GMT</pubDate>
<description>PARIS, April 25, 2025--Regulatory News: ALIKO SCIENTIFIC (Ikonisys SA) (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique, fully automated solution for medical analysis laboratories, today announces the postponement of the publication of its 2024 annual financial report, initially scheduled on April 30, 2025, to no later than May 31, 2025.</description>
</item>
</channel>
</rss>